MoonLake Immunotherapeutics (MLTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 45.26 |
| Open | 45.31 |
| Bid | 44.40 x 100 |
| Ask | 44.83 x 100 |
| Day's range | 44.29 - 45.56 |
| 52-week range | 24.31 - 64.98 |
| Volume | |
| Avg. volume | 474,935 |
| Market cap | 2.799B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings date | 12 May 2024 - 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 71.00 |
Business WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland, April 10, 2024--MoonLake Immunotherapeutics ("MoonLake"; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active
Simply Wall St.MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Investor's Business DailyMoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.
© 2024 Yahoo. All rights reserved.